SignalCorporate
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
Q3 loss reported alongside revenue exceeding estimates.
Context
What happened: Rhythm Pharmaceuticals ($RYTM) reported a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a $0.68 loss, and revenue of $92.13 million beat the consensus estimate.
Key numbers: Loss per share $0.61 vs. estimate $0.68, and $0.82 a year ago. Earnings surprise +10.29%. Revenue $92.13 million vs.
Why it matters: The company has surpassed consensus EPS and revenue estimates in each of the last four quarters. The report notes the stock's near-term movement will depend mostly on management's commentary on the earnings call.
Market: +0.9% today ($93.44), -11.0% YTD — as of 11:00 UTC
Coverage: 3 outlets in 24h
What changed
Rhythm Pharmaceuticals ($RYTM) reported a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a $0.68 loss, and revenue of $92.13 million beat the consensus estimate.
Why it matters
The company has surpassed consensus EPS and revenue estimates in each of the last four quarters. The report notes the stock's near-term movement will depend mostly on management's commentary on the earnings call.
Market: +0.9% today ($93.44), -11.0% YTD — as of 11:00 UTC